Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised …
…, C Katlama, JM Gatell, A Lazzarin, D Vittecoq… - The Lancet, 2007 - thelancet.com
Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity
against HIV-1 strains including those resistant to currently available antiretroviral drugs. The …
against HIV-1 strains including those resistant to currently available antiretroviral drugs. The …
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
…, J Cox, J Reynes, P Morlat, D Vittecoq… - The Journal of …, 2013 - academic.oup.com
Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1)
integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in …
integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in …
High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics
…, PM Girard, B Wyplosz, D Vittecoq… - Clinical Infectious …, 2015 - academic.oup.com
Background. Multidrug-resistant Enterobacteriaceae (MRE) are widespread in the community,
especially in tropical regions. Travelers are at risk of acquiring MRE in these regions, but …
especially in tropical regions. Travelers are at risk of acquiring MRE in these regions, but …
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo …
…, M RAPHAEL, E TEICHER, C VERNY, D VITTECOQ… - The Lancet, 2021 - thelancet.com
Background Shortening the duration of antibiotic therapy for patients admitted to hospital
with community-acquired pneumonia should help reduce antibiotic consumption and thus …
with community-acquired pneumonia should help reduce antibiotic consumption and thus …
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled …
H Izzedine, JS Hulot, D Vittecoq… - Nephrology Dialysis …, 2005 - academic.oup.com
Background. Tenofovir disoproxil fumarate (TDF) was developed for the treatment of human
immunodeficiency virus (HIV) infection. However, controlled data are sparse on the long-…
immunodeficiency virus (HIV) infection. However, controlled data are sparse on the long-…
Renal safety of tenofovir in HIV treatment-experienced patients
H Izzedine, C Isnard-Bagnis, JS Hulot, D Vittecoq… - Aids, 2004 - journals.lww.com
The safety of tenofovir disoproxil fumarate (TDF) was assessed in two double-blind, placebo-controlled
studies. Furthermore, we retrospectively collected 19 cases of TDF-associated …
studies. Furthermore, we retrospectively collected 19 cases of TDF-associated …
[PDF][PDF] Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus
Liver transplantation in patients coinfected with human immunodeficiency virus (HIV) and
hepatitis C virus (HCV) is a recent indication. In a single center, we have compared the survival …
hepatitis C virus (HCV) is a recent indication. In a single center, we have compared the survival …
PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis
…, A Karras, D Bazin-Kara, C Cazorla, D Vittecoq… - Journal of …, 2015 - Elsevier
Background & Aims The aim of this study was to analyse the safety and efficacy of the
PegIFNα/ribavirin/protease inhibitor combination in severe and/or refractory hepatitis C virus (HCV)…
PegIFNα/ribavirin/protease inhibitor combination in severe and/or refractory hepatitis C virus (HCV)…
Urolithiasis in HIV-positive patients treated with atazanavir
…, K Asselah, T May, D Neau, D Vittecoq - Clinical Infectious …, 2007 - academic.oup.com
Among protease inhibitors, atazanavir has not been associated with urolithiasis in clinical
studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human …
studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human …
Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease
…, AM Fillet, D Costagliola, D Vittecoq… - The Journal of …, 2005 - rupress.org
To determine the correlates of immune recovery from active human CMV (HCMV) disease,
we compared the antigenic repertoire, diversity, magnitude, and differentiation of HCMV-…
we compared the antigenic repertoire, diversity, magnitude, and differentiation of HCMV-…